Metabolomics identifies plasma biomarkers of localized radiation injury.

A radiological accident may result in the development of a local skin radiation injury (LRI) which may evolve, depending on the dose, from dry desquamation to deep ulceration and necrosis through unpredictable inflammatory waves. Therefore, early diagnosis of victims of LRI is crucial for improving medical care efficiency. This preclinical study aims to identify circulating metabolites as biomarkers associated with LRI using a C57BL/6J mouse model of hind limb irradiation.

Fetal Mortality in the United States: Final 2021-2022 and 2022-Provisional 2023.

Objectives: This report describes changes in total, early, and late fetal mortality between 2022 and 2023 (provisional), as well as fetal mortality by maternal race and Hispanic origin and state of residence. Comparisons are made with findings from 2021 to 2022.

Methods: Data are based on reports of fetal death filed in the 50 states and the District of Columbia and collected via the National Vital Statistics System.

Coronal Malalignment Is Infrequently Present in Patients With Aseptic Tibial Loosening.

Background: Coronal lower extremity malalignment and improper implant position have been described as risk factors for aseptic tibial loosening following primary total knee arthroplasty (TKA). However, several prior studies have shown no association between alignment and implant loosening. Meanwhile, there is increasing interest in kinematic alignment.

Safety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.

Follicular lymphoma (FL) is a disease often characterized by chronic and successive relapses after first-line chemoimmunotherapy. Although chemoimmunotherapy and combination therapy, such as lenalidomide with rituximab, are well established in the treatment sequence of FL, there is a need to streamline treatment options and determine placement of novel agents, such as chimeric antigen receptor T-cell therapy, an enhancer of zeste homolog 2 inhibitor, or a phosphoinositide 3 kinase inhibitor, into the treatment landscape. As such, the purpose of this review is to compare the safety profiles of approved agents in subsequent lines of therapy for relapsed or refractory FL and to assess how the management of adverse events may impact treatment choice.